




RealRate

PHARMACEUTICAL 2012

American BIO Medica CORP
Rank 106 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of American BIO Medica CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of American BIO Medica CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 96% points. The greatest weakness of American BIO Medica CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 2.7% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	4,276
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,391
Liabilities, Non-Current	751
Other Assets	56
Other Compr. Net Income	0
Other Expenses	7,381
Other Liabilities	124
Other Net Income	9.0
Other Revenues	9,272
Property and Equipment	1,304
Research and Development	223
Selling, General and Administrative Expense	2,022

Output Variable	Value in 1000 USD
Assets	5,636
Liabilities	3,266
Expenses	9,626
Revenues	9,272
Stockholders Equity	2,370
Net Income	-345
Comprehensive Net Income	-345
BaseVar	13,904
ECR before LimitedLiability	108%
Economic Capital Ratio	237%